Sector Expert: John Hester
John Hester is a senior healthcare equities analyst at Bell Potter Securities. He is based in Sydney, Australia, and specializes in small and mid-cap healthcare, biotechnology and industrial stocks. Bell Potter is a leading Australian broker servicing institutional, high net worth and retail clients. Previously, Hester worked at LINWAR Securities and Select Equities, where he led the firms' coverage of the listed healthcare sector and diversified financials. Hester's experience in the healthcare sector is drawn from many years' experience at Primary Healthcare, where he gained firsthand experience in the operation of general practice, imaging and pathology from one of Australia's leading healthcare organizations. His network of contacts includes executives at the highest levels within numerous companies, fund managers, commercial banks and investment bankers. More recently, he has extended his expertise to certain biotechnology stocks and has considerable industry knowledge in the field of oncology and emerging therapies therein.
Play the Gap to Profit from Australia's Undervalued Biotech Gems: John Hester of Bell Potter Securities (7/22/15)
Investors who lament missing the U.S. biotech bull market might have another avenue to pursue. Biotech valuations in Australia are not in sync with U.S. biotech valuations, and comparable stocks from Down Under may have extraordinary technology platforms and huge upside potential. In this interview with The Life Sciences Report, Senior Healthcare Analyst John Hester of Bell Potter Securities discusses two hidden Australian biotech gems, one of which could ride the coattails of a U.S.-based product on a very positive regulatory path.